GlassScriptPhysician profile
Stanley C Mannino
NPI 1487645727
$1,183.62
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $273 · 2021: $198 · 2022: $18.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.14 | 2019-2021 | |
| Abbott Laboratories | $150.12 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $149.34 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.16 | 2019-2021 | |
| Amarin Pharma, INC. | $139.10 | 2019-2021 | |
| Medtronic Vascular, INC. | $115.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $86.91 | 2019-2021 | |
| Amgen INC. | $81.76 | 2019-2020 | |
| Pfizer INC. | $40.10 | 2019 | |
| Terumo Medical Corporation | $25.14 | 2021 | |
| Boston Scientific Corporation | $21.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.39 | 2022 | |
| Astellas Pharma US INC | $15.72 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Mannino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.